Skip to main content

Month: September 2024

Better Choice Company to Present at the 2024 ThinkEquity Conference and Provides Detail on Sales in China and the Acquisition of SRx Health

Sustained Sales Momentum in China in Q3 Following 37% Sequential Growth in Q2 Acquisition of SRx Health Remains On-Track TAMPA, Fla., Sept. 26, 2024 (GLOBE NEWSWIRE) — Better Choice Company (NYSE: BTTR) (“Better Choice” or “the Company”), a pet health and wellness company, today announced it will present at the ThinkEquity Conference on October 30th, 2024 at the Mandarin Oriental Hotel in New York City. During the conference, management will provide updates on its international sales performance and the ongoing acquisition of SRx Health. Key Highlights will Include:China Sales Growth: The Company continues to experience sales growth internationally, with sales from China increasing 37% sequentially for the second quarter of 2024 as compared to the first quarter of 2024. International sales account for approximately 28% of Better...

Continue reading

21Shares AG Announcement: 2024 Interim Financial Statements

26 September 2024 Announcement: 2024 Interim Financial Statements 21Shares AG, the issuer of ETPs listed on various trading venues, has published its interim financial statements for the six months ending 30 June 2024. The financial statements are available at: https://21shares.com/ir/financials Contact: Email: press@21.co Phone: +41 44 260 86 60 About 21Shares AG: 21Shares AG, Pelikanstrasse 37, 8001 Zurich, is a Swiss corporation registered in the commercial register of Zurich under the number CHE-347.562.100. It was incorporated on 27 July 2018 and its purpose is the issuance of Exchange Traded Products (ETPs) in Switzerland and worldwide.

Continue reading

Ninepoint Partners Announces Final September 2024 Cash Distribution for Ninepoint Cash Management Fund – ETF Series

TORONTO, Sept. 26, 2024 (GLOBE NEWSWIRE) — Ninepoint Partners LP (“Ninepoint Partners”) today announced the final September 2024 cash distribution for the Ninepoint Cash Management Fund – ETF Series. The record date for the distribution is September 27, 2024. This distribution is payable on October 7, 2024. The per-unit final September distribution is detailed below:Ninepoint ETF Series Ticker Cash Distribution per unit Notional Distribution per unit CUSIPNinepoint Cash Management Fund NSAV $0.15667 $0.00000 65443X105About Ninepoint Partners Based in Toronto, Ninepoint Partners LP is one of Canada’s leading alternative investment management firms overseeing approximately $7 billion in assets under management and institutional contracts. Committed to helping investors explore innovative investment solutions that have...

Continue reading

FDA Lifts Clinical Hold on BMF-219 in Type 2 and Type 1 Diabetes Trials

REDWOOD CITY, Calif., Sept. 26, 2024 (GLOBE NEWSWIRE) — Biomea Fusion, Inc. (“Biomea” or the “Company”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing oral covalent small molecules to treat and improve the lives of patients with metabolic diseases and genetically defined cancers, today announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold on Biomea’s ongoing Phase I/II clinical trials of the Company’s investigational covalent menin inhibitor BMF-219 in type 2 and type 1 diabetes (COVALENT-111 and COVALENT-112), respectively. “We greatly appreciate FDA’s review of our data, and the swift resolution of the clinical trial hold. The in-depth review of the clinical data to date reconfirms our confidence in BMF-219 as a novel, first-in-class agent for...

Continue reading

SCOR acquires Altarea’s stake in MRM. Following the acquisition, SCOR intends to file a simplified public tender offer

Press releaseSeptember 26, 2024 – N° 13 SCOR acquires Altarea’s stake in MRM.Following the acquisition, SCOR intends to file a simplified public tender offer To read this information in full, please confirm that you have read and understood the disclaimer on SCOR’s website here. * *        *SCOR, a leading global reinsurer   As a leading global reinsurer, SCOR offers its clients a diversified and innovative range of reinsurance and insurance solutions and services to control and manage risk. Applying “The Art & Science of Risk”, SCOR uses its industry-recognized expertise and cutting-edge financial solutions to serve its clients and contribute to the welfare and resilience of society.   The Group generated premiums of EUR 19.4 billion in 2023 and serves clients in around 160 countries from its 35 offices worldwide.   For...

Continue reading

Healthcare costs at a post-pandemic high, US employers prioritize affordability and wellbeing

Plan redesign outweighs cost-shifting to reduce the cost of care, WTW survey finds NEW YORK, Sept. 26, 2024 (GLOBE NEWSWIRE) — As the cost of healthcare in the U.S. rises to a record high since the COVID-19 pandemic, nearly half of employers expect healthcare costs will exceed budget projections this year. In response, employers are embracing different approaches to safeguard program affordability for their companies as well as for their employees. While focusing on more competitive, cost-effective plan designs to control costs, they are seeking to maintain employee wellbeing, according to a new survey by WTW (NASDAQ: WTW), a leading global advisory, broking and solutions company. WTW’s 2024 Best Practices in Healthcare Survey found that U.S. employers project their healthcare costs will increase by 7.7% in 2025, compared with...

Continue reading

First Bank Announces Third Quarter 2024 Earnings Conference Call

HAMILTON, N.J., Sept. 26, 2024 (GLOBE NEWSWIRE) — First Bank (Nasdaq Global Market: FRBA) invites participation in a conference call to discuss the Company’s financial and operating performance during its third quarter ending on September 30, 2024.Event: Earnings Conference Call – Third Quarter 2024     When: Thursday, October 24, 2024 at 9:00 a.m. Eastern Time     Access: Conference Call Dial-In: (800) 715-9871 (toll free)        Conference Call Access Code: 1578641     Patrick L. Ryan, President and Chief Executive Officer, Andrew L. Hibshman, Chief Financial Officer, Peter J. Cahill, Chief Lending Officer, and Darleen Gillespie, Chief Retail Banking Officer will provide an overview of third quarter 2024 results. The management presentation typically lasts approximately fifteen to thirty minutes, followed...

Continue reading

Proactis SA – announcement January 2024

    Proactis SA announces results for the 18 months period ended 31 January 2024 Paris – 26th September 2024 – Proactis SA (Euronext: PROAC), a leading provider of comprehensive spend management and business process collaboration solutions, today announced financial information for the year ended 31 January 2024, in accordance with the “European Transparency Obligations Directive” financial disclosure requirements. It should be noted at the outset that publication of the results for the year ended January 31, 2024, was originally scheduled for May 31, 2024. Unfortunately, Proactis SA was unable to keep to this timetable, as its statutory auditors were unwilling to issue their reports on the accounts for the period just ended before the completion of the audit of the accounts of Proactis SA’s parent company by the group’s UK...

Continue reading

The 30-Year Fixed-Rate Mortgage Reaches Lowest Level in Two Years

Primary Mortgage Market Survey®U.S. weekly average mortgage rates as of 09/26/2024MCLEAN, Va., Sept. 26, 2024 (GLOBE NEWSWIRE) — Freddie Mac (OTCQB: FMCC) today released the results of its Primary Mortgage Market Survey® (PMMS®), showing the 30-year fixed-rate mortgage (FRM) averaged 6.08 percent. “Although this week’s decline was slight, the 30-year fixed-rate mortgage trended down to its lowest level in two years,” said Sam Khater, Freddie Mac’s Chief Economist. “Given the downward trajectory of rates, refinance activity continues to pick up, creating opportunities for many homeowners to trim their monthly mortgage payment. Meanwhile, many looking to purchase a home are playing the waiting game to see if rates decrease further as additional economic data is released over the next several weeks.” News FactsThe 30-year...

Continue reading

OSE Immunotherapeutics Announces Historic H1 2024 Results and Provides Corporate Update

OSE Immunotherapeutics Announces Historic H1 2024 Results and Provides Corporate Update Financial and business highlightsTotal H1 2024 incomes of €82.5 million thanks to Company’s new partnerships. New strategic partnership with AbbVie for up to $713 million, including $48 million received upon signature. Major partnership expansion with Boehringer Ingelheim:Amendment of the collaboration and licensing agreement on first-in-class SIRPα compounds developed both in immuno-oncology and now expected in Phase 2 in cardiovascular-renal-metabolic diseases: a one-time payment of €25.3 million. New asset acquisition of a preclinical program from the OSE’s cis- targeting anti-PD1/cytokine platform: €13.5 million received upon signature and €17.5 potential near-term milestone.€8.4 million in non-dilutive funding under the “i-Démo” call...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.